Thor Medical ASA (FRA:8NN) Other Current Receivables: €0.79 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8NN Thor Medical ASA FRA:8NN
32 GF Score
Price €0.40
! 2 Warning Signs
View Full Analysis

What is Thor Medical ASA Other Current Receivables?

Thor Medical ASA FRA:8NN +2.06% 32 Other Current Receivables is €0.79 Mil as of Dec. 2025. GuruFocus rates FRA:8NN with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Thor Medical ASA's Other Current Receivables for the quarter that ended in Dec. 2025 was €0.79 Mil.

Thor Medical ASA's quarterly Other Current Receivables increased from Dec. 2024 (€0.36 Mil) to Jun. 2025 (€1.85 Mil) but then stayed the same from Jun. 2025 (€1.85 Mil) to Dec. 2025 (€0.79 Mil).

Thor Medical ASA's annual Other Current Receivables increased from Dec. 2023 (€0.23 Mil) to Dec. 2024 (€0.36 Mil) and increased from Dec. 2024 (€0.36 Mil) to Dec. 2025 (€0.79 Mil).

Thor Medical ASA Other Current Receivables Related Terms

Thor Medical ASA Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Thor Medical ASA's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thor Medical ASA Other Current Receivables Chart

Thor Medical ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.48 0.23 0.36 0.79

Thor Medical ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.36 0.36 1.85 0.79
FRA:8NN
32GF Score
Thor Medical ASA FRA:8NN
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thor Medical ASA Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.79 Mil mean?
Thor Medical ASA (FRA:8NN) has a Other Current Receivables of €0.79 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Thor Medical ASA and its competitors.
Is Thor Medical ASA's Other Current Receivables too high?
Thor Medical ASA's current Other Current Receivables is €0.79 Mil. Overall, Thor Medical ASA has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's Other Current Receivables compare to VRTX and REGN?
Thor Medical ASA's Other Current Receivables of €0.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Thor Medical ASA and its competitors. Thor Medical ASA's current Other Current Receivables is €0.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current Other Current Receivables of €0.79 Mil. The current Other Current Receivables is €0.79 Mil. Thor Medical ASA's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current Other Current Receivables is €0.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thor Medical ASA Business Description

Other Exchanges TRMED:Norway0R6Y:UK
Address Drammensveien 167, Oslo, NOR, 0277
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
32GF Score

Get the complete analysis for FRA:8NN

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price